Valuation: Castle Biosciences, Inc.

Market Cap 1.08B 957M 895M 815M 1.53B 104B 1.56B 10.82B 4.19B 52.81B 4.04B 3.96B 170B P/E 2026 *
-27.8x
P/E 2027 * -37.5x
Enterprise Value 1.08B 957M 895M 815M 1.53B 104B 1.56B 10.82B 4.19B 52.81B 4.04B 3.96B 170B EV / Sales 2026 *
2.89x
EV / Sales 2027 * 2.62x
Free-Float
97.58%
Yield 2026 *
-
Yield 2027 * -
1 day-0.77%
1 week+0.18%
Current month-0.77%
1 month+5.43%
3 months+42.68%
6 months+40.74%
Current year-9.37%
1 week 34.14
Extreme 34.1375
36.99
1 month 31.44
Extreme 31.44
36.99
Current year 17.72
Extreme 17.722
44.28
1 year 17.72
Extreme 17.722
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
68.65
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 2007-08-31
Director of Finance/CFO 56 2017-11-30
Chief Tech/Sci/R&D Officer - 2021-06-30
Director TitleAgeSince
Director/Board Member 64 2007-08-31
Chairman 64 2014-08-31
Director/Board Member 70 2018-12-05
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Exercice

Founder

31,656 0.1036%
9/15/26 Sell

Executive/Senior Manager

-3,294 0.0108%
9/11/26 Exercice

Founder

31,686 0.1037%
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%+0.18%+53.15%+108.73% 1.09B
-2.17%-4.33%-27.56%-0.17% 171B
+0.17%-2.34%-8.83%+10.31% 110B
-0.88%+1.19%-25.04%-0.11% 106B
-0.69%-0.07%-47.78%-12.45% 75.99B
+3.17%-0.03%-0.64%+72.13% 57.3B
-0.52%-0.65%-6.74%-31.12% 48.76B
-1.37%+2.30%+12.85%+58.48% 50.19B
-0.85%+0.85%-16.51%+18.41% 41.14B
-0.07%-1.42%+30.49%-7.58% 32.56B
Average -0.41%-0.23%-3.66%+21.66% 69.4B
Weighted average by Cap. -0.66%-1.02%-16.30%+9.12%

Financials

2026 *2027 *
Net sales 373M 331M 310M 282M 532M 35.93B 539M 3.75B 1.45B 18.3B 1.4B 1.37B 58.77B 412M 366M 342M 312M 587M 39.63B 595M 4.14B 1.6B 20.18B 1.55B 1.51B 64.83B
Net income -37.78M -33.56M -31.38M -28.6M -53.84M -3.64B -54.58M -380M -147M -1.85B -142M -139M -5.95B -25.64M -22.78M -21.3M -19.41M -36.54M -2.47B -37.04M -258M -99.74M -1.26B -96.27M -94.19M -4.04B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
1,002
Date Price Change Volume
26-10-01 US$35.26 -0.77% 522,288
26-09-30 US$35.53 +1.86% 639,605
26-09-29 US$34.88 -2.92% 318,619
26-09-28 US$35.93 +0.34% 228,425
26-09-25 US$35.81 +1.76% 437,681
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
35.26USD
Average target price
45.11USD
Spread / Average Target
+27.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock